The majority of seasonal flu inoculations (78%) have been given to children, and of those, the most popular brand has been MedImmune's FluMist. At least 246,000 FluMist inoculations were administered through the week ending Aug. 29, which accounted for 66% of vaccinations for patients under age 18.
SDI maintains the largest influenza-monitoring program in the United States and has tracked, measured, and forecast the number of people affected by cough, cold, influenza, and other upper respiratory conditions to assist clients and consumers alike for over 25 years.
Each year in the United States, on average, more than 200,000 people are hospitalized and 36,000 people die from seasonal flu complications. The Centers for Disease Control and Prevention recommends a yearly seasonal flu vaccine as the first and most important step in protecting against seasonal flu. A new vaccine against novel H1N1 is being produced and will be available in the coming months as an option for prevention of novel H1N1 infection.
About SDI
SDI is a leading healthcare market insight and analytics firm. It provides the industry's most comprehensive de-identified patient-level data to pharmaceutical, biotech, and medical device companies, enabling them to better understand the healthcare market. SDI also serves the government and the financial services, media, and consumer packaged goods industries. Founded in 1982, SDI counts the world's top 50 pharmaceutical and biotech firms as its clients.
SOURCE: SDI
SDI Tracy Everly, 267-685-4387 teverly@sdihealth.com or Buchanan Public Relations Jack Loughran, 610-649-9292 jack@buchananpr.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index